56 GSK Annual Report 2018 Group financial review continued Cash generation and conversion A summary of the consolidated cash flow statement is set out below.
Free cash flow 2018 2017 Free cash flow is the amount of cash generated by the Group after m m meeting our obligations for contingent consideration, interest, tax Net cash inflow from operating activities 8,421 6,918 and dividends paid to non-controlling interests, and after capital Net cash outflow from investing activities 1,553 1,443 expenditure on property, plant and equipment and intangible assets.
Net cash outflow from financing activities 6,389 6,380 2017 Increase decrease in cash and bank overdrafts 479 905 2018 revised m m Cash and bank overdrafts at beginning of year 3,600 4,605 Free cash inflow 5,692 3,485 Increase decrease in cash and bank overdrafts 479 905 Exchange adjustments 8 100 Free cash flow was 5,692 million for the year 2017 3,485 Cash and bank overdrafts at end of year 4,087 3,600 million.
The increase primarily reflected improved operating profits, a smaller increase in working capital following a reduction of inventory Cash and bank overdrafts at end of year balances and a strong focus on collections, the favourable timing of comprise: payments for returns and rebates, reduced legal settlement costs Cash and cash equivalents 3,874 3,833 and restructuring payments, lower capital expenditure, including a Cash and cash equivalents reported in assets favourable comparison with the impact of the Priority Review Voucher held for sale 485 in 2017, increased disposals of intangible assets of 256 million Overdrafts 272 233 2017 48 million, primarily relating to the disposal of tapinarof, 4,087 3,600 and reduced dividend payments to non-controlling interests.
This was partly offset by a negative currency impact on operating profit The net cash inflow from operating activities for the year was 8,421 and increased contingent consideration payments including the million 2017 6,918 million.
The increase primarily reflected $450 million 317 million milestone paid to Novartis in the year.
improved operating profits, a smaller increase in working capital as a result of a reduction of inventory balances and a strong focus on Reconciliation of net cash inflow from operating collections, the favourable timing of payments for returns and rebates, activities to free cash flow and reduced legal settlement and restructuring payments, partly offset by a negative currency impact on operating profit.
A reconciliation of net cash inflow from operating activities, which is the closest equivalent IFRS measure to free cash flow, is shown Total cash payments to Shionogi in relation to the ViiV Healthcare below.
contingent consideration liability in the year were 793 million 2017 671 million, of which 703 million was recognised in cash 2017 2018 revised flows from operating activities and 90 million was recognised in m m contingent consideration paid within investing cash flows.
These Net cash inflow from operating activities 8,421 6,918 payments are deductible for tax purposes.
Purchase of property, plant and equipment 1,344 1,545 Purchase of intangible assets 452 657 Capital expenditure and financial investment Proceeds from sale of property, plant and equipment 168 281 Cash payments for tangible and intangible fixed assets amounted Proceeds from disposal of intangible assets 256 48 to 1,796 million 2017 2,202 million and disposals realised Interest paid 766 781 453 million 2017 807 million.
Cash payments to acquire Interest received 72 64 equity investments amounted to 309 million 2017 80 million, Dividends from associates and joint ventures 39 6 primarily relating to 23andMe, and sales of equity investments realised 151 million 2017 64 million.
Contingent consideration paid reported in investing activities 153 91 Contribution from non-controlling interests 21 21 Distributions to non-controlling interests 570 779 Free cash flow 5,692 3,485 57 GSK Annual Report 2018 Strategic report Governance and remuneration Financial statements Investor information Cash generation and conversion continued Future cash flow Working capital Over the long term, we expect that future cash generated from 2018 2017 operations will be sufficient to fund our operating and debt servicing Working capital percentage of turnover % 23 22 costs, normal levels of capital expenditure, obligations under Working capital conversion cycle days 201 191 existing licensing agreements, expenditure arising from restructuring programmes and other routine outflows including tax, pension The increase of 10 days in 2018 compared with 2017 was contributions and dividends, subject to the Principal risks and predominantly due to an adverse impact from exchange of uncertainties discussed on pages 241 to 250.
We may from time to approximately five days as well as a reduced denominator due to time have additional demands for finance, such as for acquisitions, lower restructuring and impairment costs in 2018.
Excluding these including potentially acquiring increased ownership interests in the factors, significant improvements were made in working capital ViiV Healthcare business where minority shareholders hold put relative to the growth in the business, with reduced inventory as a options.
We have access to multiple sources of liquidity from short result of tight control of inventory levels and stronger collections of and long-term capital markets and financial institutions for such receivables.
needs, in addition to the cash flow from operations.
Investment appraisal and capital allocation We have a strong framework for capital allocation, including a board to govern the allocation of capital between our businesses.
We utilise a consistent cash return on invested capital CROIC methodology to prioritise investment across the Group as a whole, so that we can more effectively compare the returns from each of the businesses as we allocate capital between them.
We also consider the impact on EPS and our credit profile where relevant.
The discount rate used to perform financial analyses is decided internally, to allow determination of the extent to which investments cover our cost of capital.
For individual investments the discount rate may be adjusted to take into account specific country, business or project risk.
